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Tylophorine Analogs Allosterically 
Regulates Heat Shock Cognate 
Protein 70 And Inhibits Hepatitis C 
Virus Replication
Ying Wang1,2, Sangwon Lee1, Ya Ha1, Wing Lam1, Shao-Ru Chen2, Ginger E. Dutschman1, 
Elizabeth A. Gullen1, Susan P. Grill1, Yao Cheng1, Alois Fürstner3, Samson Francis4, David C. 
Baker4, Xiaoming Yang5, Kuo-Hsiung Lee5,6 & Yung-Chi Cheng1
Tylophorine analogs have been shown to exhibit diverse activities against cancer, inflammation, 
arthritis, and lupus in vivo. In this study, we demonstrated that two tylophorine analogs, DCB-3503 
and rac-cryptopleurine, exhibit potent inhibitory activity against hepatitis C virus (HCV) replication 
in genotype 1b Con 1 isolate. The inhibition of HCV replication is at least partially mediated through 
cellular heat shock cognate protein 70 (Hsc70). Hsc70 associates with the HCV replication complex 
by primarily binding to the poly U/UC motifs in HCV RNA. The interaction of DCB-3503 and rac-
cryptopleurine with Hsc70 promotes the ATP hydrolysis activity of Hsc70 in the presence of the 3′ poly 
U/UC motif of HCV RNA. Regulating the ATPase activity of Hsc70 may be one of the mechanisms by 
which tylophorine analogs inhibit HCV replication. This study demonstrates the novel anti-HCV activity 
of tylophorine analogs. Our results also highlight the importance of Hsc70 in HCV replication.
Tylophorine analogs are a class of natural products first isolated from the plant Tylophora Indica1. Tylophora 
Indica and Tylophora Ovata were traditionally used for the treatment of asthma in India2 and arthritis in China3. 
This group of analogs has also shown broad activities against cancer4, 5, inflammation5, 6, arthritis3, and lupus7 
in vivo. Tylophorine analogs have been shown to reduce the rate of elongation of polypeptide chain to inhibit 
global protein synthesis8, which has a more profound effect on cellular regulatory proteins with short half-lives8. 
No other known anticancer drug or protein synthesis inhibitors exhibits the same novel activity. Only vascular 
endothelial growth factor receptor 2 (VEGFR2) has been identified for the antiangiogenic activity of tylophorine9. 
In addition, we recently identified that tylophorine analog DCB-3503 regulated translation of cyclin D1 through 
allosteric regulation of heat shock cognate protein 70 (Hsc70)10.
Hepatitis C virus (HCV) infects approximately 3% of the world’s population and is one of the top reasons for 
the development of liver cirrhosis and hepatocellular carcinoma11. The nonstructural (NS) proteins are respon-
sible for replication of HCV RNA and virus particle assembly and are primary antiviral targets12, 13. The initial 
standard of care for HCV infection is peginterferon alpha combined with ribavirin for 48 weeks for HCV geno-
type 1, or 24 weeks for HCV genotypes 2 or 3. Peginterferon treatment showed a sustained viral response (SVR) 
rate of less than 50% HCV genotype 1 infection, the most prevalent strain in Europe and North America11. The 
recently developed direct-acting antivirals (DAAs) targeting against NS proteins significantly improved SVRs to 
as high as 99% and broadened the spectrum of patients to all genotypes as well as HCV with cirrhosis patients14–16. 
However, the high cost of current treatment restricts broad patient access, especially to the DAAs. In addition, 
targeting host factors by small molecules could illustrate the important functions of host factors involved in viral 
replication and pathogenesis17.
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Tylophorine analogs inhibit selected set of protein syntheses by inhibiting the elongation step8. Both HCV 
replication and protein synthesis take place on the endoplasmic reticulum (ER). Therefore, we explored whether 
tylophorine analogs could inhibit replication of HCV. We hypothesized that DCB-3503 inhibits elongation 
by interacting with host factors; thus we aimed to identify cellular target(s) of the tylophorine analogs regu-
lating translation and viral replication. Using biotinylated-DCB-35034 and -rac-cryptopleurine18, we identified 
heat shock cognate protein 70 (Hsc70) as one of the cellular targets of tylophorine analogs. Hsc70 is a consti-
tutively expressed heat shock protein family member with an ATPase N-terminal nucleotide-binding domain 
(NBD) and a C-terminal substrate-binding domain (SBD)19. The ATPase activity of Hsc70 could be regulated by 
small-molecule inhibitors and/or cochaperone proteins20.
In this study, we demonstrated that DCB-3503 and rac-cryptopleurine potently inhibit HCV replication. They 
both exhibit anti-HCV activity by promoting the ATP hydrolysis activity of Hsc70 through binding to the 3′ poly 
U/UC motif of HCV RNA. This allosteric regulation of Hsc70 function alters the interaction between Hsc70 and 
its associated HCV protein and RNA, and also perturbs the homeostasis of the HCV replication complex, thus 
inhibiting translation of HCV RNA.
Results
Tylophorine analogs exhibit anti-HCV activity in HCV genotype 1b replicon cells. We previously 
demonstrated that DCB-3503 and its analogs inhibit protein synthesis8, 21. Protein synthesis is one of the most 
critical steps in HCV replication11; therefore, we examined the anti-HCV activity of the tylophorine analogs, 
DCB-3503 and rac-cryptopleurine8, 21–23 in Huh-luc/neo-ET cells harboring the HCV genotype 1b Con 1 isolate. 
Treatment with DCB-3503 and rac-cryptopleurine decreased HCV RNA levels (Fig. 1a and b) and the expression 
of NS3 and NS5A proteins in a dose-dependent manner (Fig. 1c and d). No resistant clones could be isolated 
after selection with a 10-fold EC50 concentration of DCB-3503 (300 nM) and rac-cryptopleurine (30 nM) for 
three weeks (Figure S1a). While resistant clones emerged under the selection of a 10-fold EC50 concentration of 
meso-tetrakis-porphyrin compound 6 (200 nM), a potent HCV inhibitor developed in our laboratory that targeta 
viral protease (Figure S1a)24.
Tylophorine analog specifically interacts with Hsc70. Since we could not isolate resistant clones 
to DCB-3503 or rac-cryptopleurine, we hypothesized that tylophorine analogs may inhibit viral replication by 
affecting host factors. Biotinylated DCB-3503 and rac-cryptopleurine were synthesized to determine the molec-
ular target(s) of the tylophorine analogs. The tethered biotin group was connected to the 3-position on the tylo-
phorine backbone as directed by our structure–activity relationship study8, 10, 21–23 (Figure S1b). The anti-HCV 
activity and cytotoxicity of both parental compounds and biotinylated derivatives are shown in Table S3. The 
flow chart of affinity purification was shown in Figure S1c. The proteins bound to biotinylated-DCB-3503 and 
Figure 1. DCB-3503 and rac-cryptopleurine exhibit anti-HCV activity in HCV genotype 1b (Con1) replicon 
cells. The level of HCV RNA and cell viability after treatment with various concentrations of (a) DCB-3503 or 
(b) rac-cryptopleurine. The expression level of HCV RNA was analyzed by real-time PCR and normalized to 
that of β-actin. Expression of NS3 and NS5A in the (c) DCB-3503 and (d) rac-cryptopleurine-treated HCV 
replicon cells were analyzed by Western blot. β-Actin served as the internal loading control. The results are 
representative of at least three independent experiments, error bars represent standard deviations.
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-rac-cryptopleurine were separated by SDS-PAGE and visualized by silver staining. Proteins that specifically 
eluted by rac-cryptopleurine were identified by LTQ Orbitrap mass spectrometry10. Western blot analysis results 
revealed that biotinylated DCB-3503 and rac-cryptopleurine bound to Hsc70 when Huh-luc/neo-ET cell lysate or 
recombinant polyhistidine (His)-tagged Hsc70 was run through the compound matrix column (Fig. 2a). Hsp70 
or Hsp90 did not bind to the affinity matrix under the same conditions (Fig. 2a). Increasing concentration of ATP 
(Fig. 2b) but not UTP (Fig. 2c) eluted the compound-bound Hsc70. The binding was also dependent on ionic 
strength: 0.4 M NaCl eluted the bound Hsc70 from the affinity matrix (Figure S1d). Western blot results showed 
that both DCB-3503 and rac-cryptopleurine bound to the NBD of recombinant Hsc70 (residue 1–385) (Fig. 2d). 
The binding affinity of DCB-3503 and rac-cryptopleurine to Hsc70 did not change when a D206S mutation was 
introduced into the ATPase pocket in the NBD of Hsc70 (Fig. 2e)25. In order to determine antibody specificity, 
we expressed and purified recombinant Hsp70. Western blot results indicated that the Hsc70 antibody we used 
recognized only recombinant Hsc70 but not Hsp70 (Figure S1e). Isothermal titration calorimetry (ITC) revealed 
that DCB-3503 and rac-cryptopleurine showed similar binding affinities to the full length (FL) and the NBD of 
Hsc70 (Table 1 and Figure S1f). The protein level of Hsc70 remained unchanged throughout the treatment with 
DCB-3503 or rac-cryptopleurine for up to 72 hours (Figure S1g).
Figure 2. Tylophorine analogs interact with Hsc70. (a) Hsc70, but not Hsp70 or Hsp90, bound specifically 
to rac-cryptopleurine or DCB-3503 affinity resin. (b) Bound recombinant Hsc70 was eluted with increasing 
concentrations of ATP. The Hsc70 in each fraction was resolved by Western blot. (c) Bound recombinant 
Hsc70 was eluted with 50 µM ATP or UTP. Hsc70 in each fraction was resolved by Western blot. (d) His-tagged 
different fragments of Hsc70 were incubated with streptavidin-agarose beads coated with biotinylated-rac-
cryptopleurine or -DCB-3503. Bound proteins were immunoblotted with anti-His tag antibody. (e) His-
tagged Hsc70 protein harboring D206S mutation was incubated with streptavidin-agarose beads pre-bound 
to biotinylated-rac-cryptopleurine or -DCB-3503. Bound proteins were immunoblotted with anti-His tag 
antibody. Results are representative of at least three independent experiments.
Compound Protein n Kd (M) ΔH (kCal/mol) ΔS (cal/(mol·K))
DCB-3503 Hsc70 FL 0.41 2.8 ± 0.5 3079 35.7
DCB-3503 Hsc70 NBD 0.49 4.4 ± 0.9 5135 41.7
rac-Cryptopleurine Hsc70 FL 0.57 3.1 ± 0.33 2019 32.0
rac-Cryptopleurine Hsc70 NBD 1.06 2.7 ± 0.48 1905 31.9
Table 1. Thermodynamic parameters obtained from the ITC measurement of the binding between tylophorine 
analogs and Hsc70.
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Hsc70 is involved in the anti-HCV activity of DCB-3503. We constructed an Hsc70 overexpres-
sion plasmid with silent mutation on the shRNA targeting sites (rHsc70-1, and rHsc70-2, Fig. 3a) to deter-
mine the off-target effect of shRNA. Down-regulation of Hsc70 with shRNA reduced HCV RNA replication 
and suppressed expression of NS3 and NS5A (lanes 3 and 5 in Fig. 3b). The RNAi phenotype was partially res-
cued by over-expressing HA-rHsc70s (Fig. 3b), suggesting that suppression of Hsc70 was responsible for the 
down-regulation of HCV replication. Transfection of wild type (WT) HA-tagged Hsc70 also inhibited HCV 
RNA replication (Fig. 3b, quantitative results of protein expression are shown in Figure S2a). shRNA knockdown 
of Hsc70 for 48 hours enhanced the anti-HCV activity of DCB-3503 as reflected by the resultant decrease in 
HCV RNA, NS3, and NS5A levels (Fig. 3c, quantitative results of protein expression were shown in Figure S2b). 
Reduced expression of Hsc70 by shRNAs did not significantly affect cell growth (Figure S2c). Complete knockout 
of Hsc70 with combination of two shRNAs is lethal to cells; thus, a more significant anti-HCV effect could not be 
Figure 3. Tylophorine analogs exhibit anti-HCV activity via interaction with Hsc70 in HCV genotype 1b 
(Con1) replicon cells. (a) The shRNA-resistant Hsc70 with nucleotide substitution in the 21-mer targeting 
sequences were constructed without changing amino acids (rHsc70-1, rHsc70-2). (b) Huh-luc/neo-ET cells 
were transiently transfected in a six-well plate with 400 ng HA-Hsc70 plasmid (WT, R-1, and R-2), alone or in 
combination with either Hsc70 shRNAs or empty vector (EV), for 36 hours. Levels of HCV RNA, NS3, NS5A, 
Hsc70, and HA-Hsc70 were analyzed by real-time PCR and Western blot, respectively. β-Actin served as the 
internal loading control. (c) Huh-luc/neo-ET cells were transiently transfected in a six-well plate with 400 ng 
Hsc70 shRNA or empty vector (EV). The cells were either treated with 30 nM DCB-3503 or untreated 24 hours 
after transfection. HCV RNA and expression of Hsc70 were examined by Real-Time PCR and Western blot, 
respectively. The numbers under the bands indicate normalized relative band intensity. (d) Huh-luc/neo-ET 
cells were transiently transfected in a six-well plate with 1 μg WT HA-Hsc70, D206S mutant HA-Hsc70 plasmid, 
or EV. DCB-3503 was added 24 hours after transfection and treated for another 48 hours. HCV RNA was 
examined by Real-Time PCR. The expression levels of NS3, NS5A, NS5B, HA tag, and Hsc70 were examined 
by Western blot. β-Actin served as an internal loading control. (e) Transient transfection of HCV RNA into 
Hsc70 knocked-down HLN-cure cells. 400,000 HLN-cure cells transfected with Hsc70 shRNAs or empty 
vector 72 hours earlier were transiently transfected with HCV RNA by electroporation. HCV replication was 
monitored by luciferase assay at 24, 48, 72, and 96 hours post-electroporation. The luciferase activity 24 hours 
post-electroporation in empty vector transfected HLNC cells was set as 1-fold. The expression levels of Hsc70 
before and after electroporation are shown in Figure S2e. Results are representative of at least three independent 
experiments. Error bars represent standard deviations from three independent experiments. #p < 0.1, *p < 0.05, 
**p < 0.01.
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demonstrated. Overexpression of either WT or D206S mutant HA-tagged Hsc70 inhibited expression levels of 
HCV RNA and NS proteins, and further enhanced the anti-HCV effect of DCB-3503 (Fig. 3d, quantitative results 
of protein expression are shown in Figure S2d) without changing the cell growth curve (Figure S2e). Treatment 
with DCB-3503 inhibited translation of HCV in vitro (Figure S2f), and pretreatment of HLN-cured cells with 
30 nM DCB-3503 for 24 hours reduced the cells’ ability to support HCV replication by about 2-fold (Figure S2g). 
Furthermore, the replication rate of HCV RNA transfected into HLN-cured cells with reduced Hsc70 expres-
sion by shRNA was about 3-fold slower than those HLC-cured cells without Hsc70 shRNA treatment (Fig. 3e). 
The Hsc70 expression levels are shown in Figure S2h. Alteration of expression of Hsc70 is related to HCV RNA 
replication.
Hsc70 is associated with the HCV replication complex. Hsc70 exhibits its function via association 
with different cellular complexes26. We thus examined whether Hsc70 is associated with the HCV replication 
complex. Post-nuclear supernatant of untreated, DCB-3503-treated or rac-cryptopleurine-treated Huh-luc/
neo-ET cells were fractionated on continuous optiprep iodixanol density gradients (Figs 4a–c, S2i). The optiprep 
density gradients separated membrane vesicles (Alix and Hrs as markers in fractions 1–6, and GRP 78 as marker 
in fractions 1–2), and endoplasmic reticulum (ER) (GRP78 and Calenxin as markers in fractions 7–11) (Fig. 4a). 
In untreated control cells, HCV RNA, NS3, and NS5A exhibited the same sedimentation with the membrane 
vesicles and ER in fractions 5–11 (Fig. 4a and b), a result consistent with the density reported earlier27. In cells 
treated with DCB-3503 or rac-cryptopleurine; however, HCV RNA, NS3, and NS5A agglomerated with the ER in 
fractions 8–11 (Fig. 4a and b). Hsc70 showed the same sedimentation shift with the membrane vesicles (fractions 
1–3) and ER (fractions 7–11) in both untreated control and drug-treated cells (Fig. 4a). DCB-3503 accumulated 
in the first two fractions with 60–80 nM concentration where Hsc70 was primarily located (Fig. 4c). In addition, 
DCB-3503 was found in fractions 3–12 at around 1 nM concentration (Fig. 4c). The amount of rac-cryptopleurine 
in the fractions was too low to detect with LC/MS/MS. The cosedimentation of Hsc70 with HCV NS3, NS5A, 
and ER marker Calnexin was disrupted when the cytoplasmic fraction was treated with 0.5 M NaCl or RNase 
Figure 4. Hsc70 associates with HCV replicon complex. (a) Partition of NS3, NS5A, Hsc70, Calnexin, GRP78, 
Alix, and Hrs from fractions obtained from control Huh-luc/neo-ET cells and cells treated with either 30 nM 
DCB-3503 (DCB) or 3 nM rac-cryptopleurine (R-crypto) for 48 hours. (b) The relative HCV RNA content in 
fractions obtained in (a) was analyzed by Real-Time PCR. (c) The concentration of DCB-3503 in each fraction 
was analyzed by LC–MS/MS. The insert shows the zoomed-in results of fractions 5–12. (d) Cytosolic fractions 
of untreated Huh-luc/neo-ET cells and cells treated with 30 nM DCB-3503 or 3 nM rac-cryptopleurine for 
48 hours were treated with 0.5 M NaCl, 0.1% SDS, or 0.1 μg/μl RNase A for 2 hours before being subjected to 
centrifugation to isolate CRC. The presence of NS3, NS5A, Hsc70, Calnexin, and GRP78 were analyzed by 
Western blot. P and S denote the pellet and the supernatant of centrifuged samples, respectively. Results are 
representative of at least three independent experiments.
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A before centrifugation to isolate crude HCV replicon (Fig. 4d). All the examined proteins were found only in 
the supernatant fraction with addition of 0.1% SDS (Fig. 4d). NS3 and NS5A remained in the membrane-rich 
pellet fraction when ionic strength was changed with NaCl, or when the RNA was depleted with RNase treatment 
(Fig. 4d). However, addition of 0.5 M NaCl or 0.1 μg/μl of RNase released Hsc70 from the membrane-rich pellet 
fraction to the supernatant (Fig. 4d). Addition of 0.1% SDS totally disrupted the membrane structure and released 
NS3, NS5A, and Hsc70 to the supernatant (Fig. 4d).
Treatment with DCB-3503 promotes binding of Hsc70 to HCV RNA. Given the result of the 
co-sedimentation of Hsc70 with HCV NS proteins and RNA, we further examined the association of Hsc70 
with HCV replication complex. Real-time PCR results showed that more than 30% of HCV RNA was present 
in the Hsc70 immunoprecipitated complex (Fig. 5a). The level of HCV RNA in the input and Hsc70-associated 
complex did not change significantly after treatment with up to100 nM DCB-3503 for 6 hours. However, the 
amount of Hsc70-associated NS5A and NS5B were reduced with treatment of 30 nM and 100 nM of DCB-3503 
for 6 hours (Fig. 5a). NS3/4 A, NS4B, or host RNAs (β-actin and survivin) did not bind to Hsc70 under the same 
conditions (Figs 5a and S3a,b). RNase A treatment decreased the amount of NS5A and NS5B associated with 
Hsc70 (Figure S3c). We then analyzed the association between NS5B and Hsc70 and between HCV RNA and 
NS5B using a co-immunoprecipitation method. DCB-3503 treatment reduced the amount of Hsc70 bound to 
Figure 5. Tylophorine analogs stimulated the ATP hydrolysis function of Hsc70 modulating its association 
with HCV RNA. (a) Hsc70-associated HCV RNA and protein was immunoprecipitated with Hsc70 antibody. 
The level of HCV RNA was examined by real-time PCR. Protein levels of NS3, NS5A, NS5B, and Hsc70 were 
analyzed by Western blot. (b) The schematic graph showed the RNA sequences used in Fig. 5c,d. Nucleotide 
positions correspond to the HCV genotype 1b complete genome isolate Con1 (GI 5420376). (c) Either 
streptavidin beads alone or in vitro transcribed biotinylated RNA with the sequences shown in (b) were mixed 
with purified Hsc70 protein. RNA-bound Hsc70 was detected by Western blot analysis. (d) Unlabeled RNA was 
used to compete the binding with biotinylated short poly U/UC RNA for binding to Hsc70. (e) The schematic 
graph shows the poly U/UC region of HCV genotype 2a (JFH-1, GI 13122261). The binding assay was done 
as shown in (d). Results of (a)–(e) are representative from at least three independent experiments. Effect of 
(f) DCB-3503, (g) rac-cryptopleurine, or (h) 2-phenylethanesulfonamide (PES) on the Km of Hsc70 for ATP 
binding in the presence or absence of short poly U/UC or poly C RNA. The concentration of generated ADP 
was analyzed and calculated based on the area under the curve (AUC). The Km and Vmax values were calculated 
by fitting the data to the Michaelis–Menten kinetics equation. Error bars represent standard deviations from 
three independent experiments. Results are representative of at least three independent experiments and 
presented as mean ± SD. P values are labeled on the graph.
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HA-tagged NS5B when immunoprecipitated with HA antibody (Figure S3d). The association of NS5B and Hsc70 
to biotinylated HCV RNA was also decreased with addition of DCB-3503 (Figure S3e). Hsc70 can bind to the 
AU-rich elements in the 3′ untranslated region of Bim mRNA28. Thus, we generated constructs with different 
specific motifs of the 3′ nontranslated region (3′ NTR) of HCV genotype 1b RNA to determine the Hsc70 binding 
RNA sequence (Fig. 5b)29. Hsc70 bound to all the biotinylated RNA fragments containing AUUUA and poly U/
UC sequences (Fig. 5c). Biotinylated RNA containing only the AUUUA sequence showed relatively weak asso-
ciation with Hsc70 compared with poly U/UC RNA (Fig. 5d). Hsc70 was not associated with Poly A RNA under 
the same conditions (Fig. 5c). The association of short poly U/UC RNA with Hsc70 was comparable to that of 
other longer RNA fragments (Fig. 5c), which suggests that the poly U/UC sequence is essential but not necessarily 
sufficient for binding to Hsc70. The poly U/UC RNA below refers to the short form of HCV genotype 1b. Poly 
U/UC RNA did not bind to fragments of Hsc70 (Figure S3f) or Hsp70 (Figure S3g) under the same conditions. 
Addition of increasing concentrations of unlabeled poly U/UC or AU + UC RNA competed with the association 
of biotinylated poly U/UC RNA to Hsc70 in a dose dependent manner (Fig. 5d). As much as 9-fold of unlabeled 
AUUUA RNA could not compete with poly U/UC binding with the same efficiency (last three lanes, Fig. 5d). 
Deletion of the poly U/UC region in the 3′ NTR could not support HCV replication (Figure S3h). Since the poly 
U/UC region in the 3′NTR of the HCV genome is conserved through all genotypes29, we then generated the poly 
U/UC region of HCV genotype 2a JFH1 clone (Fig. 5e) and performed the RNA-binding assay under the same 
conditions. Biotin labeled poly U/UC RNA of HCV genotype 2a also bound to Hsc70 and the increasing amount 
of unlabeled poly U/UC RNA decreased the association to Hsc70 (Fig. 5e) as poly U/UC RNA from HCV geno-
type 1b (Fig. 5d).
Tylophorine analogs stimulate the ATPase activity of Hsc70 in the presence of poly U/UC 
RNA. The association between Hsc70 and interacting proteins or RNAs is primarily regulated by its ATPase 
activity19. We determined the ability of tylophorine analogs to regulate the ATPase activity of Hsc70. DCB-
3503 and rac-crytopleurine stimulated ATP hydrolysis of FL Hsc70 only at relatively high concentrations 
(Figure S4a and b). Meanwhile, the Km of Hsc70 for ATP-binding was reduced to about 50% by DCB-3503 or 
rac-cryptopleurine in the presence or absence of poly U/UC RNA (Fig. 5f and g). Addition of an equal amount 
of poly C RNA into the reaction did not change the Km for ATP-binding by DCB-3503 and rac-cryptopleurine 
under the same conditions (Fig. 5f and g). Hsp70 inhibitor 2-phenylethanesulfonamide (PES)25 did not change 
Km (Fig. 5h), while PES inhibited hydrolysis of ATP by increasing Km for ATP-binding in the presence of poly U/
UC RNA (Fig. 5h). The Vmax of Hsc70 for ATP hydrolysis did not change significantly under the same conditions 
by DCB-3503, or rac-cryptopleurine, or PES (Figure S4c–e).
Co-chaperone protein BAG1 is involved in the anti-HCV activity of tylophorine ana-
logs. Co-chaperone proteins regulate the ATPase activity of Hsc70 by modulating the ATP/ADP hydrolysis 
cycle30. The co-chaperone protein BAG-1 is bound to a conserved BAG domain of Hsc70 that interacts with its 
ATPase domain30. To determine the function of BAG1 in the anti-HCV activity of the tylophorine analogs, we 
constructed an HA-tagged BAG1 plasmid and transfected it into Huh-luc/neo-ET cells. The expression level 
of BAG1 was not affected by DCB-3503 treatment for up to 6 hours (Fig. 6a); however, the amount of BAG1 
that bound to Hsc70 was decreased with the DCB-3503 treatment (Fig. 6a). Transfection of HA-tagged BAG1 
enhanced the inhibitory activity of DCB-3503 and rac-cryptopleurine on HCV RNA replication, as well as 
expression levels of NS3 and NS5A (Fig. 6b,c). The expression level of HA-BAG1 was decreased with DCB-3503 
and rac-cryptopleurine treatment for 48 hours (Fig. 6b,c).
Discussion
The tylophorine analogs have exhibited various activities, yet the only molecular target VEGFR2 revealed for this 
group of compounds was associated with their anti-cancer activities9. One report has suggested that tylopho-
rine or (–)-(R)-tylophorine attenuated HCV IRES-mediated translation by suppressing expression of cyclin A231. 
However, results of our structure–activity relationship studies suggested that tylophorine was not a functional 
analog of DCB-3503 and rac-cryptopleurine8, 21–23. Our study revealed that DCB-3503 stimulated the ATPase 
activity of Hsc70, thus inhibited translation of cyclin D1 mRNA10. In this study, we evaluated both five- and 
six-membered E-ring tylophorine analogs as potent inhibitors of HCV replication (Figures 1 and S1a). No resist-
ant clones could be isolated with either DCB-3503 or rac-cryptopleurine treatment (Figure S1a), suggesting that 
the tylophorine analogs inhibit HCV replication through modulation of the functions of the host’s factor(s).
Hsc70 is associated with the HCV replication complex. Host chaperones and co-chaperones play 
important functions in the assembly of the viral replication complex and the replication of the viral genome. 
Hsc70 participated in the RNA-dependent replication of sindbis virus32, influenza virus33, rotavirus34, and dengue 
virus35. Hsc70 also associated with lipid droplet in HCV-infected cells36. Suppression of Hsc70 expression using 
shRNAs decreased the infectivity of the HCV J6/JFH virion36. DNAJC14 regulated the chaperone activity of 
Hsp70; over-expression of DNAJC14 disrupted the stoichiometry of the chaperone/substrate and assembly of the 
yellow fever virus replication complex37.
We demonstrated that HCV RNA mediated the binding of Hsc70 to the HCV replication complex (Figs 4 and 5). 
Part of Hsc70 exhibited the same sedimentation with NS3, NS5A, and HCV RNA in the continuous gradient 
fractions (Fig. 4a,b). The association of Hsc70 to the membrane-rich fraction containing the HCV replication 
complex was disrupted by changing the ionic strength or RNase treatment, which suggested that the association 
was dependent on RNA (Fig. 4d and S3c). DCB-3503 treatment perturbed the association of NS5A and NS5B to 
Hsc70 (Figures 5a and S3d,e), but increased the amount of HCV RNA bound to Hsc70 (Fig. 5a). Hsc70 specifi-
cally bound to the poly U/UC RNA motif in both HCV genotypes 1b and 2a (Figs 5b–e and S3f,g). The poly U/
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UC RNA motif is critical for the efficient translation and replication of HCV RNA efficiently38, 39. Deletion of the 
poly U/UC sequence inhibited replication of HCV in subgenomic replicon cells (Figure S3f)29, 38. An HCV viral 
genome lacking this element was not infectious40. Therefore, we presume that DCB-3503 and rac-cryptopleurine 
could also inhibit replication of other genotypes, for example HCV genotype 2a and its quasispecies that maintain 
the 3′NTR poly U/UC motif. Poly U/UC was essential for binding to replication factors like the FUSE binding 
protein41 and hnRNP A142. These RNA-binding proteins regulated translation through either stabilization of 
RNA or promotion of RNA decay43. A single nucleotide base change sharply reduced the binding affinity between 
Hsc70 and its associated AUUUA motif in the 3′ untranslated region of host mRNAs10. We found that tylopho-
rine analogs did not inhibit replication of HIV or HBV (results not shown). HIV and HBV have very different 
sequences from that of HCV, especially in that they do not contain the poly U/UC motif in the 3′NTR. These 
results suggest that Hsc70 is associated with HCV replication complex preferentially through binding to the 
uridine rich motif in the 3′NTR.
Two previous reports demonstrated that suppression of Hsc70 by using siRNAs or small molecule inhibitors 
did not affect HCV RNA replication but rather impacted on the release of virons36, 44. The conflict results may be 
due to the genotype difference of the Con1 isolate used in the present study from that of the J6/JFH isolated with 
infectivity36, 44. In addition, sequence and structure differences in the regulatory elements of HCV, like 5′NTR 
and 3′NTR may require different regulating elements that contribute to differential infectivity and replication45. 
Therefore, it is reasonable that we obtained results there were different from the previous reports36, 44.
Hsc70 is involved in HCV replication through regulating the translation of HCV RNA. We iden-
tified Hsc70 as one of the molecular targets of functional tylophorine analogs using biotinylated-DCB-3503 and 
-rac-crytopleurine (Figures 2 and S1). The function of Hsc70 is regulated by communications between NBD and 
SBD. The ATP-bound form of Hsc70 has a “loose” configuration with low affinity for substrates; the ADP-bound 
state of Hsc70 shows high affinity with associated proteins or RNA46, and favors degradation of substrates47. For 
example, binding of Hsc70 but not Hsp70 to CHIP promoted its degradation through ubiquitination48. ATP 
hydrolysis of Hsc70 NBD induces a conformational switch in the adjacent SBD that enhances its binding affinity 
to substrates.
The binding between Hsc70 and tylophorine was affected by ATP concentration (Fig. 2b,c). DCB-3503 and 
rac-cryptopleurine bind to the D206S ATPase mutant form of Hsc70, suggesting that the functional ATPase 
pocket was not required for the interaction (Fig. 2e). Either attenuation of Hsc70 expression level or ectopic 
expression of the WT or D206S mutant form of Hsc70 enhanced the anti-HCV activity of DCB-3503 (Figs 3b–
d and S2a,b, and d). The binding of DCB-3503 or rac-crytopleurine to Hsc70 stimulated its ATPase activity 
in the presence of the poly U/UC motif of HCV RNA (Fig. 5f,g) without affecting Hsc70 protein expression 
(Figure S1g). Over-expression of co-chaperone protein BAG-1, which regulates the chaperone activity of Hsc70 
Figure 6. Co-chaperone protein BAG-1 regulate anti-HCV activity of tylophorine analogs. (a) DCB-3503 
treatment decreased interaction of co-chaperone protein BAG-1 and Hsc70. Huh-luc/neo-ET cells were 
transiently transfected with HA- BAG-1 plasmid. The cells were treated with 30 nM DCB-3503 48 hours after 
transfection. Hsc70-associated HA-BAG-1 was immunoprecipitated with Hsc70 antibody as shown in Fig. 5a. 
Protein levels of HA-BAG-1 and Hsc70 were analyzed by Western blot. Huh-luc/neo-ET cells were transiently 
transfected in a six-well plate with 400 ng HA- BAG-1 plasmid or empty vector alone or in combination with 
(b) 30 nM DCB-3503, or (c) 3 nM rac-cryptopleurine for 36 hours. Levels of HCV RNA, NS3, NS5A, and HA-
BAG-1 were analyzed by real-time PCR and Western blot, respectively. β-Actin served as the internal loading 
control. Results are representative of at least three independent experiments and presented as mean ± SD. P 
values are labeled on the graph.
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by promoting ATP hydrolysis function of Hsc7049, significantly enhanced the anti-HCV activities of DCB-3503 
and rac-cryptopleurine (Fig. 6b,c). Therefore, modulating the homeostasis of the ATP/ADP hydrolysis cycle of 
Hsc70 by tylophorine analogs is related to the inhibitory activity to HCV RNA replication. The HCV RNA asso-
ciated to Hsc70 in the ADP binding state may be sent to degradation as other substrates of Hsc70. Suppression 
of Hsp70 expression by its inhibitor, quercetin, attenuated the IRES-mediated translation of HCV J6/JFH virus50. 
It is also possible that perturbation of Hsc70 function markedly reduced the activities of NS5A and NS5B in the 
reduced level of free HCV RNA. The around 1 nM concentration of DCB-3503 accumulated in each fraction of 
fractions 5–12 (Fig. 4c) revealed that DCB-3503 could be associated with protein or a subcellular complex instead 
of existing in the free form. The concentration should be decreased sharply from fraction 3–12 if DCB-3503 was 
in the free form. Only co-localization of DCB-3503, NS proteins, and Hsc70 could make this possible. Regulating 
the ATPase activity of Hsc70 by DCB-3503 and rac-cryptopleurine may be one of the mechanisms by which these 
compounds modulate HCV replication.
Allosteric regulation of Hsc70 is an alternative strategy to regulate HCV replication. ATPase 
activity of Hsc70 could be regulated by co-chaperones and/or small molecules, including the Bag (Bcl 
2-associated athanogene) family of proteins30, 49, the Hsp40 family proteins51, the immunosuppressive agent 
15-deoxyspergualin (DSG)52, or lycoricidine and analogs53, 54. DSG is associated with the EEVD domain in the 
C-terminal of Hsc70 and Hsp9055. N-substituted benzyl matrinic acid derivatives, ( + )-lycoricidine and analogs 
inhibited HCV replication through suppression of Hsc70 expression53, 54, 56.
Hsc70 is an abundant cellular protein; therefore, ectopic expression of Hsc70 could not suppress HCV repli-
cation (Fig. 3b–d)57. Constitutive deletion of Hsc70 is embryonically lethal in mice, causing defects in multiple 
organs58. We also observed that knockdown of Hsc70 by combined shRNAs induced cell death. Thus, allosteri-
cally modulating ATPase activity of Hsc70 could be a better option to perturb its function rather than decreasing 
its expression. DCB-3503 and rac-cryptopleurine binds to the NBD of Hsc70 but not HSP90 nor Hsp70 (Figures 2 
and S1d) without changing the expression of Hsc70 (Figure S1g). Ectopic expression of BAG1, which promoted 
ATP hydrolysis activity of Hsc7030, significantly enhanced the anti-HCV activity of tylophorine analogs (Fig. 6). 
The allosteric regulation of Hsc70 by DCB-3503 and rac-cryptopleurine is distinct from that of existing Hsc70 
inhibitors and has not been reported previously. To our knowledge, the tylophorine analogs are the first known 
class of small molecules that associated with the NBD of Hsc70 and promote the hydrolysis of ATP (Fig. 5f and g).
Taken together, we propose the following model for the mechanisms of action for the anti-HCV activity of 
functional tylophorine analogs. DCB-3503 or rac-cryptopleurine binds to the NBD of Hsc70 independent of the 
intact ATP pocket. The binding stimulates the ATP hydrolysis of Hsc70 in the presence of the poly U/UC motif of 
HCV RNA, and thus inhibits translation. The tylophorine analogs may be potentially used with other anti-HCV 
agents to attenuate HCV replication. We demonstrated that DCB-3503 exhibited anti-cancer and anti-arthritis 
activities4, 5, 10; therefore, this group of tylophorine analogs could have special advantages for the treatment of can-
cer and/or autoimmune diseases patients infected with HCV. However, many questions remain to be investigated. 
For example, the exact tylophorine binding site(s) of Hsc70 is (are) still unclear due to our failed attempt to deter-
mine the Hsc70-DCB-3503 or Hsc70-rac-cryptopleurine complex by crystallography. Will the specific binding to 
the poly U/UC motif in HCV genotype 2a also be related to anti-HCV activity? And, the dynamic regulation by 
the tylophorine analogs of ATP/ADP turnover in Hsc70 remains unexplained.
Experimental procedures
Materials and reagents. Cell culture media and fetal bovine serum (FBS) were purchased from Invitrogen. 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) except for those otherwise noted. The DCB 
series of compounds were synthesized in Dr. Baker’s laboratory. rac-Cryptopleurine and biotinylated-rac-cryp-
topleurine were synthesized in Dr. Alois Fürstner’s laboratory. The YXM series of compounds were synthe-
sized in Dr. Kuo-Hsiung Lee’s laboratory. The PA series of compounds were provided by Dr. Shishan Yu22. 
2-Phenylethanesulfonamide (PES) was purchased from Sigma–Aldrich. Information for plasmid construction 
and real-time PCR primers are provided in Tables S1 and S2, respectively.
Affinity purification. The affinity purification method was adopted from a method reported by Emami 
et al.59. Cells were lysed in protein-binding buffer [PBB, 20Mm Hepes, pH 7.9, 100 mM NaCl, 0.5 mM 
EDTA, 0.5% Nonidet P-40, 6 mM MgCl2, 5 mM 2-mercaptoethanol, complete protease inhibitor (Roche)]. 
Biotinylated-rac-cryptopleurine and -DCB-3503 were bound overnight at room temperature to a 50% slurry of 
streptavidin–agarose beads (Invitrogen) in buffer containing 50% DMSO and 50% PBB. Beads were washed to 
remove unbound compound and then incubated with pre-cleared whole-cell lysates or recombinant protein in 
2.5% BSA. Bound proteins were eluted, either specifically with rac-cryptopleurine or DCB-3503, or with a buffer 
specified in the figures. Proteins that remained bound to beads were eluted with SDS loading buffer. Samples were 
separated with SDS PAGE, and examined by Western blot or silver staining. Specific bands from silver-stained gel 
were analyzed by LTQ Orbitrap mass spectrophotometry (Yale University W.M. Keck Foundation Biotechnology 
Resource Laboratory).
Statistical analysis. Data were analyzed by a two-tailed student’s t-test (Microsoft Office Excel). The differ-
ence was considered to be statistically significant when p < 0.05.
Data availability. All data generated or analyzed during this study are included in this published article and 
its Supplementary Information files.
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